Equity Research firms currently have a positive stance on shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO). The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of 1.90. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $18.33 on a short term basis.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO)’s shares may have a significant upside to the consensus target of 18.33, but how has it been performing relative to the market? The stock’s price is 18.30 and their relative strength index (RSI) stands at 65.19. RSI is a technical oscillator that shows price strength by comparing upward and downward movements. It indicates oversold and overbought price levels for a stock.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares are moving 6.71% trading at $18.30 today.
Sell-side analysts are offering a consensus “Buy” rating on shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX). Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell and 5.0 Strong Sell, analysts have an average recommendation of 1.70. Based on a recent trade, the shares are hovering around $24.75 which, according to analysts, yield significant upside potential to the $17.86 consensus target price.
At the time of writing, the stock was trading at $24.75. This represents a change from most recent open price of 7.38%. In terms of performance, year to date, the stock is 35.62%. The monthly stock performance comes in at 55.66%. For the quarter, shares are performing at 74.91%. Weekly performance analysis shows the equity at 32.35%.
In taking a look at technical levels, shares are trading 47.62% away from the 50 day simple moving average and 181.98% away from the 200 day simple moving average. Based on a recent bid, the stock is trading 5.54% away from it’s 52- week high and 816.67% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Mirati Therapeutics, Inc.’s RSI stands at 75.18. In looking at volatility levels, the shares saw weekly volatility of 12.05% and 7.62% over the past month.